1651P - Pre-treatment Neutrophil Lymphocyte Ratio/Platelet Lymphocyte Ratio as surrogate markers of survival in non-metastatic head and neck cancer patient...

Date 11 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Head and Neck Cancers
Translational Research
Presenter Vijay Agarwal
Citation Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390
Authors V. Agarwal1, R. Rao2, H.R. Abin3, V. Rao4, R.C. Nayar4, V. Mani2, A. Ram2, B.S. Ajaikumar1
  • 1Medical Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN
  • 2Healthcare Global Enterprises Ltd., CARE, HCG Foundation, 560027 - BANGALORE/IN
  • 3Clinical Pharmacology, Acharya & BM Reddy College of Pharmacy, BANGALORE/IN
  • 4Surgical Oncology, Healthcare Global Enterprises ltd., 560027 - BANGALORE/IN

Abstract

Background

Neutrophil lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are known to be surrogate markers of inflammation and have been shown to predict mortality in patients with heart disease and cancer. In this study, we evaluate the influence of pre-treatment NLR and PLR on overall survival in head and neck cancer patients.

Methods

In this observational correlational study, subjects with a diagnosis of non-metastatic head and neck cancer were analyzed for neutrophil-lymphocyte ratio and the platelet-lymphocyte ratio at baseline before the start of their cancer-directed therapy.

Results

In this study, 189 subjects were analyzed for neutrophil-lymphocyte ratio and platelet-lymphocyte ratio before their treatment. The mean age of the study sample was 54.5±11.8. Forty-two percent underwent surgery followed by adjuvant chemoradiation while remaining underwent concurrent chemoradiation. Neoadjuvant chemotherapy was done in 29.4% of the study population. Mean NLR was 3.4±3.13 and PLR was 12.7±8.8. ROC analysis revealed 2.23 as the cutoff for NLR and 9.49 as the cutoff for PLR. Based on these cutoffs a Kaplan-Meir analysis on overall survival showed significantly improved survival (67.5% vs 58% at their mean estimates of 52 and 36 months) in those with  2.23 (Log Rank χ2=5.3, p = 0.02). Similarly, those with  9.49 (Log Rank χ2=8.1, p = 0.005). Lower NLR also showed better disease-free survival (44 vs 33 months, Log Rank χ2=4.8, p = 0.03) and lower PLR also showed better disease-free survival (44 vs 33 months, Log Rank χ2=8.2, p = 0.004).

Conclusions

Both NLR and PLR are inflammatory biomarkers in cancer. The results from this study suggest pretreatment NLR and PLR as predictive markers of survival in non-metastatic head and neck cancer patients.

Clinical trial identification

Legal entity responsible for the study

Vijay Agarwal

Funding

HCG Foundation

Disclosure

All authors have declared no conflicts of interest.